DEMI-REGROTON
LOE ApproachingNDAORALTABLET
Approved
May 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEMI-REGROTON is an oral tablet small-molecule drug approved by the FDA in 1964 under NDA classification. The mechanism of action, pharmacologic class, and specific indications are not publicly detailed in available data. This is a legacy product with a long commercial history.
LOE Approaching
Product faces imminent loss of exclusivity with moderate competitive pressure (30/100), suggesting defensive positioning and potential team restructuring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring for DEMI-REGROTON, reflecting its LOE-approaching lifecycle stage. Career growth on this product is limited; professionals should expect maintenance-mode activities focused on maximizing remaining exclusivity value rather than expansion or innovation.
Brand ManagerProduct Manager
Worked on DEMI-REGROTON at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.